Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?

Journal of Clinical Oncology

Volumn 29, Issue 13, 2011, Pages

  Potemski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; OXALIPLATIN; PLACEBO; RECOMBINANT ALPHA2A INTERFERON;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLEAR CELL RENAL CELL CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); METASTASIS; MORTALITY; NEPHRECTOMY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PHENOTYPE; POSTPROGRESSION SURVIVAL TIME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT WITHDRAWAL; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS;

EID: 79955581584     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0158     Document Type: Letter

References (10)

1. Miles D, Harbeck N, Escudier B, et al: Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 29:83-88, 2011
2. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
3. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
4. Goldhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329, 2009
5. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
6. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Results of CALGB 90206. J Clin Oncol 26:5422-5428, 2008
7. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
8. Tebbutt NC, Wilson K, Gebski VJ, et al: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study. J Clin Oncol 28:3191-3198, 2010
9. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
10. Escudier B, Bellmunt J, Négrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010